Interfron-beta1(zifron) effect on clinical improvement and mortality of COVID-19 in Imam-Reza hospital of Tabriz

Abstract

Therapies that target the virus alone cannot control severe pathogen infections. Therefore, the use of therapies that control the inflammatory response seems necessary; Therefore, according to the above, the aim of this study was to evaluate the effect of interferon-beta 1 (zifron) on clinical improvement and prognosis of patients with COVID-19 in Imam Reza (AS) Hospital in Tabriz. Materials and Methods: 200 patients with Covid 19 admitted to Imam Reza Hospital (affiliated to Tabriz University of Medical Sciences) were included in the study by available sampling method and after random assignment to the relevant groups were included. These patients received the recommended antiviral treatment in the national protocol, Kaletra (loprnavir-Ritonavir), and in addition to targeting the patient's inflammatory response, these patients were treated with interferon-beta 1 (zifron) at a dose of 250 micrograms subcutaneously. The overnight form was administered up to a maximum of 5 doses. Indicators of survival rate, recovery rate, lung recovery rate, respiratory tract status and mortality rate were compared between the two groups and the data were analyzed and compared with relevant statistical tests. P less than 0.05 was considered significant. Results: Patients treated with interferon beta-1 did not show any difference in terms of improvement of respiratory tests compared to patients in the control group. Compared to the amount after Platue variable intervention before the intervention in the control group, there was a significant difference in terms of Statistically no difference was observed in the interferon beta-1 treatment group; There was a statistically significant difference in the incidence of death between the two groups, so that the death rate in the interferon-beta-1 treatment group was significantly higher than the control group. The hospital survival rate of Covid-19 patients was up to 30 days. 28.62% for the control group and the hospital survival rate of 19 patients studied up to the 39th day, zero percent for the interferon beta-1 group was calculated.